Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Journal of Diabetes
|
June 29, 2011
Incretin-based therapies
Anthony H Stonehouse, Tamara Darsow, David G Maggs
Advances in Therapy
|
April 14, 2016
Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials
Kathrin Herrmann, Steven C Brunell, Yan Li, et al.
Mayo Clinic Proceedings
|
March 7, 2015
Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial
Carol H Wysham, Leigh A MacConell, David G Maggs, et al.
Obesity Research
|
April 20, 2004
Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients
Priscilla Hollander, David G Maggs, James A Ruggles, et al.
Diabetes Care
|
March 29, 2002
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes
Fred Whitehouse, Davida F Kruger, Mark Fineman, et al.
Diabetes/Metabolism Research and Reviews
|
January 23, 2004
Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study
David G Maggs, Mark Fineman, Jonathan Kornstein, et al.
Diabetes Care
|
March 1, 2003
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial
Priscilla A Hollander, Philip Levy, Mark S Fineman, et al.
Diabetes Care
|
March 1, 2005
Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes
Antonio Ceriello, Ludovica Piconi, Lisa Quagliaro, et al.
Diabetes/Metabolism Research and Reviews
|
April 25, 2006
Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin
Matthew C Riddle, Robert R Henry, Terri H Poon, et al.
Clinical Therapeutics
|
March 24, 2007
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
John B Buse, David C Klonoff, Loretta L Nielsen, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Journal of Diabetes
|
June 29, 2011
Incretin-based therapies
Anthony H Stonehouse, Tamara Darsow, David G Maggs
Advances in Therapy
|
April 14, 2016
Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials
Kathrin Herrmann, Steven C Brunell, Yan Li, et al.
Mayo Clinic Proceedings
|
March 7, 2015
Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial
Carol H Wysham, Leigh A MacConell, David G Maggs, et al.
Obesity Research
|
April 20, 2004
Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients
Priscilla Hollander, David G Maggs, James A Ruggles, et al.
Diabetes Care
|
March 29, 2002
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes
Fred Whitehouse, Davida F Kruger, Mark Fineman, et al.
Diabetes/Metabolism Research and Reviews
|
January 23, 2004
Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study
David G Maggs, Mark Fineman, Jonathan Kornstein, et al.
Diabetes Care
|
March 1, 2003
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial
Priscilla A Hollander, Philip Levy, Mark S Fineman, et al.
Diabetes Care
|
March 1, 2005
Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes
Antonio Ceriello, Ludovica Piconi, Lisa Quagliaro, et al.
Diabetes/Metabolism Research and Reviews
|
April 25, 2006
Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin
Matthew C Riddle, Robert R Henry, Terri H Poon, et al.
Clinical Therapeutics
|
March 24, 2007
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
John B Buse, David C Klonoff, Loretta L Nielsen, et al.
Page
of 2